Bioblast Pharma Ltd., a clinical-stage biotechnology company, focuses on the development of clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. Its product candidate is Trehalose intravenous 90mg/mL solution, a protein stabilizer and autophagy enhancer for the treatment of patients with oculopharyngeal muscular dystrophy and spinocerebellar ataxia type 3. The company was founded in 2012 and is headquartered in Tel Aviv, Israel.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-3573-6632
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees2
OptionableNot Optionable
Bioblast Pharma (NASDAQ:ORPN) Frequently Asked Questions
What is Bioblast Pharma's stock symbol?
Bioblast Pharma trades on the NASDAQ under the ticker symbol "ORPN."
When did Bioblast Pharma's stock split? How did Bioblast Pharma's stock split work?
Shares of Bioblast Pharma reverse split on the morning of Monday, September 25th 2017. The 1-5 reverse split was announced on Monday, September 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 22nd 2017. An investor that had 100 shares of Bioblast Pharma stock prior to the reverse split would have 20 shares after the split.
When is Bioblast Pharma's next earnings date?
Has Bioblast Pharma been receiving favorable news coverage?
News headlines about ORPN stock have been trending neutral this week, InfoTrie reports. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Bioblast Pharma earned a coverage optimism score of 0.3 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the near term.
Who are some of Bioblast Pharma's key competitors?
Some companies that are related to Bioblast Pharma include Kazia Therapeutics (KZIA), Endonovo Therapeutics (ENDV), Edge Therapeutics (EDGE), Innovus Pharmaceuticals (INNV), Pulmatrix (PULM), MYOS (MYOS), Onconova Therapeutics (ONTX), Amarillo Biosciences (AMAR), International Stem Cell (ISCO), ERBA Diagnostics (ERBA), DelMar Pharmaceuticals (DMPI), Wellness Center USA (WCUI), MusclePharm (MSLP), Uluru (ULUR) and Dare Bioscience (DARE).
Who are Bioblast Pharma's key executives?
Bioblast Pharma's management team includes the folowing people:
- Dr. Dalia Megiddo Ph.D., M.D., MBA, Co-Founder, MD, CEO & Director (Age 67)
- Dr. Warren W. Wasiewski, VP of R&D (Age 67)
- Prof. Avizohar Argov M.D., Special Medical Advisor to the Chief Exec. Officer and Member of Scientific Advisory Board (Age 72)
How do I buy shares of Bioblast Pharma?
Shares of ORPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bioblast Pharma's stock price today?
One share of ORPN stock can currently be purchased for approximately $1.0349.
How big of a company is Bioblast Pharma?
Bioblast Pharma has a market capitalization of $3.41 million. Bioblast Pharma employs 2 workers across the globe.
What is Bioblast Pharma's official website?
How can I contact Bioblast Pharma?
Bioblast Pharma's mailing address is PO Box 318, Tel-Aviv Is, 6100201. The biopharmaceutical company can be reached via phone at 972-3573-6632 or via email at [email protected]
MarketBeat Community Rating for Bioblast Pharma (NASDAQ ORPN)
MarketBeat's community ratings are surveys of what our community members think about Bioblast Pharma and other stocks. Vote "Outperform" if you believe ORPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORPN will underperform the S&P 500 over the long term. You may vote once every thirty days.
